Although some studies have indicated either a positive or no correlation between PD‐L1 and EGFR mutations,24 clinical evidence demonstrates the lack of efficacy of ICI monotherapy in TKI‐naive, PD‐L1‐positive, and EGFR‐mutant patients with advanced NSCLC.25 The gene discussed is EGFR; the disease is non-small cell lung carcinoma.